Literature DB >> 6208894

Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.

S Thorsen, S Müllertz, E Suenson, P Kok.   

Abstract

The pathway of plasminogen transformation was studied in plasma, particularly in relation to fibrin formation and the subsequent stimulation of plasminogen activation. Plasminogen was activated by urokinase (low fibrin-affinity) or tissue-type plasminogen activator (high fibrin-affinity). Formation of 125I-labelled free and inhibitor-bound plasminogen derivatives was quantified after their separation by acetic acid/urea/polyacrylamide-gel electrophoresis. In plasma activator converted Glu-plasminogen (residues 1-790) into Glu-plasmin, which was complexed to alpha 2-plasmin inhibitor. When this inhibitor was saturated, Glu-plasmin was autocatalytically converted into Lys-plasmin (residues 77-790). No plasmin-catalysed Lys-plasminogen formation was observed. Upon fibrin formation, activation initially followed the same Glu-plasminogen-into-Glu-plasmin conversion pathway, and stimulation of plasminogen activation was only observed with tissue-type plasminogen activator. In agreement with the emergence of novel effector function, on early plasmin cleavage of fibrin [Suenson, Lützen & Thorsen (1984) Eur. J. Biochem. 140, 513-522] the fibrin-binding of Glu-plasminogen increased when solid-phase fibrin showed evident signs of degradation. This was associated with the formation of considerable amounts of the more easily activatable Lys-plasminogen, most of which was fibrin-bound. At the same time the rate of plasmin formation with urokinase increased over that in unclotted plasma and the rate of plasmin formation with tissue-type plasminogen activator accelerated. Altogether these processes favoured enhanced fibrin degradation. The rates of Lys-plasminogen and plasmin formation abruptly decreased after lysis of fibrin, probably owing to a compromised effector function on further fibrin degradation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208894      PMCID: PMC1144278          DOI: 10.1042/bj2230179

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  The primary inhibitor of plasmin in human plasma.

Authors:  S Müllertz; I Clemmensen
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

2.  Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to epsilon-aminocaproic acid.

Authors:  S Thorsen; P Kok; T Astrup
Journal:  Thromb Diath Haemorrh       Date:  1974-12-31

3.  Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.

Authors:  S Müllertz
Journal:  Biochem J       Date:  1974-11       Impact factor: 3.857

4.  Differences in the binding to fibrin of urokinase and tissue plasminogen activator.

Authors:  S Thorsen; P Glas-Greenwalt; T Astrup
Journal:  Thromb Diath Haemorrh       Date:  1972-08-31

5.  Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.

Authors:  S M Camiolo; S Thorsen; T Astrup
Journal:  Proc Soc Exp Biol Med       Date:  1971-10

6.  Isolation and purification of a tissue plasminogen activator and its comparison with urokinase.

Authors:  P Kok; T Astrup
Journal:  Biochemistry       Date:  1969-01       Impact factor: 3.162

7.  Inhibition of urokinase by complex formation with human alpha1-antitrypsin.

Authors:  I Clemmensen; F Christensen
Journal:  Biochim Biophys Acta       Date:  1976-04-08

8.  Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.

Authors:  S Thorsen
Journal:  Biochim Biophys Acta       Date:  1975-05-30

9.  Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

Authors:  D Collen
Journal:  Eur J Biochem       Date:  1976-10-01

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more
  5 in total

1.  Kinetic studies on the effect of heparin and fibrin on plasminogen activators.

Authors:  R Fears
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

Review 2.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.

Authors:  S Müllertz; S Thorsen; L Sottrup-Jensen
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

4.  Kinetic studies on the interaction of streptokinase and other plasminogen activators with plasminogen and fibrin.

Authors:  R Fears; M J Hibbs; R A Smith
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

5.  The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.

Authors:  D Rouy; E Anglés-Cano
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.